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Abbreviations 
AD Atopic Dermatitis 
APC Antigen-presenting cells 
bp Basepair/s 
CAD Canine Atopic Dermatitis 
CAFR Cutaneous Adverse Food Reactions 
dNTP deoxyribonucleoside triphosphate 
FcεR1 High-affinity receptors on the surface of mast cells (and basophils), which 
binds the Fc region of IgE. 
indel Insertion/deletion polymorphism 
IgE Immunoglobulin E 
kb Kilobase/s 
KLK5 Kallikrein 5 
KLK7 Kallikrein 7 
LEKTI Lympho-epithelial Kazal-type related inhibitor 
LD Linkage Disequilibrium 
MHC Major Histocompatibility Complex 
NTS Netherton Syndrome 
PCR Polymerase Chain Reaction 
SCCE Stratum Corneum Chymotryptic Enzyme 
SCTE Stratum Corneum Tryptic Enzyme 
SNP Single Nucleotide Polymorphism 
SPINK5 Serine Protease Inhibitor Kazal-type 5 precursor 
TcR T-cell Receptor 
WHWT West Highland White Terrier 
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Abstract 
Atopic Dermatitis is a genetically predisposed allergic skin disease that affects both humans 
and dogs. The disease has a complex background influenced by both genetic and 
environmental factors. The genetic origin is still largely unknown but genetic screens have 
indicated several different genes or different groups of interacting genes in the aetiology of 
the disease. These genes are involved, together with environmental factors, in processes that 
lead to the expression of the clinical phenotype. In humans the genetic background is most 
likely more complex than in many dog breeds due to the intense inbreeding that many dog 
populations have experienced. Certain dog breeds are more predisposed to develop Canine 
Atopic Dermatitis (CAD) than others and high-risk breeds are for instance Boxer and West 
Highland White Terriers (WHWT). Case and control animals from these two breeds were 
included in this study where two candidate genes for CAD were evaluated. The genes 
Kallikrein 7 (KLK7) and Serine Protease Inhibitor Kazal-type 5 precursor (SPINK5) have, 
based on studies that have implicated these genes in atopic diseases, been selected as 
candidate genes for CAD.  
 
Two different kinds of genetic markers were used in the evaluation; three microsatellites in 
the near vicinity of the gene were chosen for the evaluation of KLK7, and single-nucleotide 
polymorphisms (SNPs) were searched for in one intron of SPINK5. No informative SNPs in 
the SPINK5 gene were found in WHWT (except for individual mutations) but four SNP loci 
were found within the sequenced area of 1,500 base pairs in Boxer. These SNP alleles were 
connected into two haplotypes but neither of the haplotypes showed any association with the 
disease phenotype. However, additional test individuals as well as more polymorphic 
markers, which are better spread out within and around the gene, are needed for an improved 
evaluation of SPINK5´s involvement in the disease in these two dog breeds. In KLK7, the 
three microsatellite-markers were both quite polymorphic (except for one locus in WHWT) 
and well distributed within and around the gene, and the data conclusively show lack of 
association between the gene and the disease phenotype.  
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Introduction 
The objective of this study was to evaluate whether two chosen genes were associated with 
Canine Atopic Dermatitis (CAD) in the two high-risk breeds West Highland White Terrier 
(WHWT) and Boxer. The disease CAD will be discussed in the first part of this report 
followed by a short summary of the most important components in the antigen-specific 
immune response. Earlier studies on human and mice have shown that the two genes, 
Kallikrein 7 (KLK7) and Serine Protease Inhibitor Kazal-type 5 precursor (SPINK5) could be 
involved in atopic dermatitis. In addition, the genes have shown to have important functions 
in the epidermis. These genes have therefore been chosen as candidate genes for CAD in this 
study and are described in detail later in this report. The design of the project was to search 
for informative genetic markers in the near vicinity of the two candidate genes and seek 
possible associations between these markers and the disease phenotype. Case and control 
animals were compared to each other within each of the two dog populations. 
 
The complexity of Atopic Dermatitis 
 
Atopic dermatitis (AD) has a complex background with both genetic and environmental 
influences. Complex diseases such as this are described as multifactorial since they are 
dependent on an interaction between multiple major and minor genes and also important 
environmental factors, in particular the exposure to different allergens (Barnes & Marsh, 
1998).  Numerous environmental allergens have shown to be involved in the pathogenesis of 
AD. These include dust and storage mite antigens, house dust, grass, tree and weed pollens, 
mould spores, epidermal antigens, insect antigens and various antigens such as kapok (Hill & 
DeBoer, 2001). 
  
The nature of AD can also be described as heterogenic, which means that different genes, or 
different groups of interacting genes, can lead to the expression of the clinical phenotype. A 
great variety of mutations are likely to exist among the major genes involved in the disease. 
These modulate the gene functions differently and together with a different mixture of 
environmental factors they will result in a diversity of disease expressions (Barnes & Marsh, 
1998). This is typical for a complex disease and explains the large variety of symptoms 
described in human, as well as in canine patients, with atopic diseases. 
 
Dogs have a history of intense inbreeding, which has resulted in low genetic diversification 
within different breeds of dogs. Furthermore, specific genetic disorders are predisposed in 
certain dog populations and CAD is one such clear example. Due to the small genetic 
diversity, CAD should in one particular breed have a more homogeneous origin compared 
with AD in many human populations that are more genetically diverse. The chance to find a 
certain gene or genes involved in the disease increases if the population has a low genetic 
diversity because the genetic cause should then be identical by descent within that certain 
breed. Another help in searching for genes involved is a high disease incidence within the 
selected dog population. High-risk breeds are for instance WHWT, Bullterrier and Boxer 
(Nødtvedt et al, in press). 
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Canine Atopic Dermatitis, definition and historical background 
 
CAD is defined as a genetically predisposed inflammatory and pruritic allergic skin disease 
with characteristic clinical features, most commonly associated with IgE antibodies to 
environmental allergens (Olivry et al, 2001). 
 
The first published description of canine atopic disease was in 1941 on a dog with seasonal 
signs of typical allergic symptoms such as sneezing, tearing with conjunctival infection 
(conjunctiva is the mucus membrane on the inner surface of the eye lids) and nasal blocking. 
A similar well-documented case was reported in 1960 with conjunctivitis (inflammation of 
conjunctiva), lacrimation (secretion of tears) and pruritus (itchiness). Later in the 1960s and 
early 1970s, reports of multiple cases of canine atopic diseases began to appear in the 
literature and inflammatory skin lesions were established as a manifestation of canine atopy. 
These studies reported the presence of skin diseases but no specific clinical criteria for 
diagnosis of atopic dermatitis or other allergic symptoms in dogs were described. Despite the 
lack of rigid criteria for diagnosis it was during these two decades that canine atopic diseases 
were recognized to affect primarily the skin (Griffin & DeBoer, 2001). 
 
The first published reports aimed at quantifying the frequency of clinical signs in dogs 
appeared in the 1980s. However, the criteria for diagnosis of CAD were still lacking and were 
in some cases not even specified. For the most part, the only requirement was the presence of 
pruritus (Griffin & DeBoer, 2001). 
 
In 1986, Willemse proposed a list of clinical criteria for a definitive diagnosis of CAD. In 
1998, Prélaud et al, evaluated these criteria and made an update. Though both these lists are 
helpful in determining if a dog shows signs that are consistent with CAD, they are not 
completely reliable. Other diseases such as food reactions and scabies (a contagious itch or 
mange, i.e. eczematous inflammation and loss of hair, which is caused by parasitic mites such 
as Sarcoptes scabiei (Webster´s homepage) can satisfy the criteria for CAD (Griffin & 
DeBoer, 2001). 
 
Symptoms and diagnosis of Atopic Dermatitis 
 
AD is a highly pruritic chronic inflammatory skin disease. In humans, the first clinical signs 
usually present during early infancy or childhood but can persist or start in adulthood (Leung 
& Bieber, 2003). 
 
In dogs, clinical signs are usually first detected between 6 months and 3 years of age. The 
initial signs of CAD can be seasonal or non-seasonal depending on the allergens involved. 42-
75% of the dogs with the disease have seasonal initial signs and approximately 80% of these 
are symptomatic in the spring to fall leaving the rest symptomatic in the winter (Griffin & 
DeBoer, 2001). However, the majority of dogs with CAD will eventually exhibit non-seasonal 
signs as the disease progress. A typical dog with atopic dermatitis shows signs of pruritus of 
the face, ears, paws, extremities, and/or ventrum. It has not yet been established whether 
uncomplicated CAD alone can result in primary lesions. However, secondary lesions caused 
by chronic pruritus and trauma, chronic inflammation and concurrent secondary infections or 
microbial overgrowth are commonly reported in CAD (Griffin & DeBoer, 2001).   
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The inclusion criteria for CAD described by Willemse in 1986 are shown in Table 1. The 
patient must have at least three of the major diagnostic features as well as three of the minor 
features fulfilled after the exclusion of other causes of pruritus in order to obtain the 
diagnosis. Dermatologists have, in their clinical evaluation of potentially allergic dogs, used 
this list of criteria extensively. Unfortunately, these criteria have never been evaluated 
regarding sensitivity, specificity and accuracy for diagnosis of CAD (DeBoer & Hillier, 
2001). 
 
 
Table 1. Willemse`s criteria for the diagnosis of Canine Atopic Dermatitis (Willemse et al, 1986). 
Major diagnostic features of canine atopic dermatitis 
 ● pruritis 
 ● a typical morphology and distribution 
  (i) facial and/or digital involvement or 
  (ii) lichenification of the flexor surface of the tarsal joint and/or the
  extensor surface of the carpal joint 
 ● chronic or chronically-relapsing dermatitis 
 ● an individual or family history of atopy 
 ● presence of a breed predisposition 
 
Minor diagnostic features of canine atopic dermatitis 
 ● onset of symptoms before the age of 3 years 
 ● facial erythema and cheilitis 
 ● bilateral conjunctivitis 
 ● a superficial staphylococcal pyoderma 
 ● hyperhydrosis 
 ● immediate skin test reactivity to inhalants 
 ● elevated allergen-specific IgG 
 ● elevated allergen-specific IgE   
       
 
By using a survey of seven veterinarians examining 96 patients a new list of five major 
criteria for the disease was proposed by Prélaud et al, in 1998, see Table 2 (DeBoer & Hillier, 
2001). The presence of three features from the list resulted in diagnostic accuracy of 
approximately 80% according to the study (DeBoer & Hillier, 2001).  
 
 
Table 2. Diagnostic criteria for Canine Atopic Dermatitis defined by Prélaud in 1998 (DeBoer & 
Hillier, 2001). 
Major diagnostic criteria for canine atopic dermatitis 
 ● onset of clinical signs between 6 months and 3 years 
 ● corticosteroid sensitive pruritus 
 ● ear pinnae erythema 
 ● anterior bilateral erythematous pododermatitis  
 ● cheilitis 
 
 
Regardless of which exact list is used as a “checklist” for diagnosis there is a general 
agreement that other differential diagnosis must be ruled out before a diagnosis of CAD can 
be obtained. The following diagnoses are generally considered as most important to eliminate 
from the list of the potential primary or secondary problems: flea allergy dermatitis, cutaneous 
adverse food reactions (CAFR, either hypersensitivity or non-immunological reactions), 
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scabies or other pruritic mite infestation, pruritic bacterial folliculitis, Malassezia dermatitis 
and less commonly, cornification disorders and contact dermatitis. Dogs with pruritic non-
atopic diseases, in particular food hypersensitivity and scabies, could satisfy many of the 
inclusion criteria (DeBoer & Hillier, 2001). In order to evaluate the potential contribution of 
CAFR a well-performed hypersensitivity diet trial (at least 8 weeks followed by a provocation 
period) has to be conducted. This diet trial is not always performed properly or at all, thus 
hypersensitivity to food may be a part or the whole reason for the symptoms. 
 
CAFR and CAD were not always regarded as two different diseases in the early reports. Some 
of these publications included food allergens as causes of CAD, and combining food-allergic 
dogs with those with CAD may have led to inaccurate descriptions of clinical signs of CAD 
(Griffin & DeBoer, 2001). However, many typical features are common in both CAFR and 
CAD and there have been reports on a high prevalence of CAD in dogs with CAFR (13-30%) 
(Hillier & Griffin, 2001b). There is still not enough evidence to support or refute any 
association between CAD and CAFR in dogs. In humans, on the other hand, there have been 
many experimental and clinical studies recognizing a clear relationship between food 
allergens and the development of AD. Between 30 and 40% of infants and young children 
with AD suffer from concurrent food allergies (Hillier & Griffin, 2001b). 
 
Incidence  
 
AD in humans is a worldwide public health problem with 10-20% of the children affected and 
1-3% of the adults (Leung & Bieber, 2003). In the last thirty years the incidence has increased 
two to three-fold in industrialized countries whereas the rate remains much lower in 
agricultural countries such as China, Eastern Europe and rural Africa. In addition, there are 
higher rates in urban regions compared with rural regions of developed countries and the 
disease is also more common in higher social groups (Leung & Bieber, 2003). The increasing 
incidence has been closely linked to a higher indoor allergen load, enlarged exposure to 
noxious pollutants, smaller family sizes, decreased exposure to infection at a young age, 
decreased microbial load and an increase of urbanized habitats (Hillier & Griffin, 2001a). 
 
The true incidence of CAD is currently unknown. A great difficulty in determining the 
incidence of CAD is that the owners have different interpretation of what is abnormal and 
normal scratching, and that will in turn decide whether the dog is even presented to a 
veterinarian. This means that milder forms of the disease may be underreported and therefore 
the incidence rate could be underestimated (Griffin & DeBoer, 2001). Another difficulty in 
evaluating the frequency of the disease is the great problems in giving a correct diagnosis to 
dogs with allergic symptoms since no definite diagnostic test is available. 
 
With the aim to estimate the incidence rate of CAD as well as evaluating risk factors 
connected to the disease, Nødtvedt et al, studied Swedish dogs insured by the largest animal 
insurance company in Sweden, Agria. Insurance claims records from Agria were accessed and 
all dogs with a veterinary care- and life insurance within the years 1995 to 2002 were 
included in the analysis. The incidence rate of CAD was estimated to 1.7 cases per 1,000 dog 
years at risk. Breed incidence varied greatly, with the Bullterrier in the top, with 21 cases per 
1,000 dog years at risk, followed by the Welsh Terrier, Boxer and the WHWT. Other factors 
increasing the incidence of CAD (than belonging to a risk breed) were according to the study, 
urban environment, living in central or southern Sweden or being born in the autumn 
(Nødtvedt et al, in press). 
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Heritability 
 
In a study by Shaw et al, 2004, the heritability of CAD in Golden and Labrador Retrievers 
was estimated to 0.47 (ranging from 0.13 to 0.81). The results from this study also showed the 
risk of being affected in relevance to the parents’ status. If both parents had CAD, 65% of the 
offspring displayed CAD signs, 21% to 57% of the offspring developed the disease if one 
parent was atopic and only 11% of the offspring was classified with CAD if both parents were 
non-atopic. These results were in agreement with studies made in humans. This shows clearly 
that CAD has a strong genetic predisposition.  
 
Inflammatory response in cutaneous allergic reactions 
 
Several inflammatory cells have been reported to play a role in the pathogenesis of AD. 
However, some cell types seem to be of greater importance for the disease than others, these 
include mast cells, B-lymphocytes, allergen-specific helper T-lymphocytes, Langerhan’s cells 
and dermal dendritic cells (Hill & Olivry, 2001). Below follows a description of these cells in 
order to briefly picture how the immune system works and how it is involved in the disease 
development. The antibody IgE, produced by B-lymphocytes, is also an important component 
in allergic reactions and will be described as well. 
 
Mast cells 
 
Mast cells are found in the connective tissue and mostly in the areas of the body that interface 
with the environment i.e. skin, lung and gastrointestinal tract. Mast cells synthesize and 
release inflammatory mediators such as histamine, proteases and cytokines. In an allergic 
reaction, this process is usually triggered by the interaction between allergens and allergen-
specific IgE. These allergen-IgE complexes are then bound to high affinity FcεR1 receptors 
that are expressed on the mast cell’s surface. The mediators are released through a complex 
series of biochemical reactions involving G-proteins, tyrosine kinases, inositol-triphosphate, 
protein kinase C, calcium channel activation and rearrangement of the cytoskeleton. Once 
released into the extra-cellular space, the mast cell mediators assist in interplay between the 
microvasculature and other inflammatory cells. Although this response has evolved as a 
protection against parasites, it is often directed towards harmless environmental antigens and 
thereby contributes to the development of allergic diseases such as AD (Thoday et al, 2000).  
 
Antigen-presenting cells 
 
Antigen-presenting cells (APCs), are found in the gastrointestinal tract, the skin, in the 
lymphoid organs as well as in other tissues where antigen can enter the body. The APCs main 
functions are to take up antigen, process and present them to T-lymphocytes in a MHC-
restricted manner (see below), and provide co-stimulatory signals for activation of naïve T-
lymphocytes. The most important of the APCs are the bone marrow-derived cells of the 
myeloid lineage, e.g. dendritic cells that are found in many tissues. The dendritic cells are the 
major APC for initiating primary T-cell responses (Coico et al, 2003). 
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Langerhan’s cells are immature dendritic cells found in the epidermal layer of the skin. Their 
main function is to trap and transport protein antigens to the lymph nodes. Langerhans cells 
mature into lymph node-dendritic cells during their passage to the lymph nodes (Abbas et al, 
2004). 
 
Lymphocytes 
 
Lymphocytes are one type of white blood cells. They are continuously produced in the bone 
marrow, circulate in the blood and lymphatic systems and reside in lymphoid organs. There 
are two main populations of lymphocytes; B-lymphocytes and T-lymphocytes (Goldsby et al, 
2000). 
 
B-lymphocytes mature in the bone marrow and as they leave the marrow, expression of a 
unique antigen-binding receptor, which is a membrane-bound antibody molecule, is initiated 
in each B-lymphocyte. When a B-lymphocyte for the first time encounters the antigen, which 
matches its membrane-bound antibody, the binding between antigen and antibody causes the 
B-lymphocyte to proliferate. The cells produced differentiate into memory and effector B-
cells, called plasma cells. The fully differentiated plasma cell is committed to secrete large 
amounts of antibody molecules with specificity for a single antigen that triggered the B-
lymphocyte activation (Goldsby et al, 2000).  
 
T-lymphocytes mature in the thymus where each cell starts to express particular T-cell 
surface-marker molecules. The most important effector molecule on T-cells is the antigen-
specific T-cell receptor (TcR) that recognizes peptide antigens presented by major 
histocompatibility complex (MHC) class I or II molecules. The presentation of antigens by 
MHC molecules to T-cells initiates an antigen-specific immune response. One type of 
additional marker molecules are co-receptors to the TcR which allows the T-cell to 
specifically recognize either MHC class I or class II molecules (Goldsby et al, 2000). There 
are two main categories of T-lymphocytes, which can be identified on the basis of their cell 
surface-markers. The first group, T-helper cells, possesses the CD4 marker, which is a co-
receptor for MHC class II molecules. These cells, after activation from an antigen-MHC class 
II molecule complex, become an effector T-cell that secretes a variety of growth factors called 
cytokines. The cytokines (Goldsby et al, 2000) stimulate B-lymphocytes to produce 
immunoglobulins, and coordinate the effects of other inflammatory cells (Hill & Olivry, 
2001). Variations in produced cytokines result in different types of immune response 
(Goldsby et al, 2000). The other group, the T-cytotoxic cells, has the CD8 marker which is 
the co-receptor for MHC class I molecules. These cells respond to foreign antigens that are 
synthesised within cells, i.e. virus particles, and are able to induce cytotoxic effects (Hill & 
Olivry, 2001).  
 
In a study by Marsella and Olivry, 2001, an increase in CD4 and CD8 T-cells and a 
predominance of CD4 T-cells in the epidermis was found in lesional skin of dogs with CAD 
when compared to non-lesional skin of affected dogs and non-affected controls.  
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IgE antibodies 
 
In an allergic reaction the T-helper cells start secreting cytokines when they are exposed to 
certain allergens. The cytokines stimulate class switching of the B-cells into IgE-production, 
which set off the immunological response through the mast cells activation (see above). 
During an ongoing allergic response, the mast cells of atopic individuals are coated with IgE 
antibodies specific for the major allergen of an individual. The mast cell coating process of 
IgE is called sensitization. In non-atopic individuals the mast cells are covered with a variety 
of IgE in small amounts that do not cause an allergic reaction (Abbas et al, 2004). 
 
In a study by Ledin et al, 2006, the plasma levels of IgE in dogs were investigated in order to 
evaluate whether they are affected by age, breed and/or health status. The IgE levels reported 
in the literature vary greatly. This inconsistency is probably due to the fact that IgE is 
normally present at very small concentrations in sera thus causing technical difficulties 
(mainly due to cross-reactivity to IgG). A new detection method, an in vitro assay 
determining specifically the absolute levels of total IgE in dog sera, was introduced in this 
study.  
 
The IgE levels from 76 adult dogs, healthy or with the diagnosis of CAD, autoimmunity or 
infections by skin parasites, were measured with the new assay. The levels ranged from 1 to 
41µg/ml and showed no correlation to breed or health status. Thus, the levels of total IgE does 
not seem to predispose a dog to be allergic according to this study (Ledin et al, 2006). These 
results are in contrast with other studies where the presence of antigen-specific IgE was 
shown to correlate with allergic symptoms (Barret et al, 2003, Masuda et al, 2002). 
 
The normal IgE-levels in humans are approximately 0.15µg/ml and in allergic humans up to 
1.5µg/ml. The higher IgE-levels in dogs may be explained from the dog’s higher exposure of 
allergens and parasites in their environment (Ledin et al, 2006). In Ledin’s study the levels of 
33 juvenile dogs showed that the IgE levels seem to increase with age, indicating that the 
exposure of antigens affect the IgE levels. In addition, dogs have a higher number of IgE 
producing B-cells compared with humans (Ledin et al, 2006).   
 
The possibility of reducing IgE levels through vaccination was also investigated by 
performing an immunization assay on nine Beagle dogs. The vaccine was designed to induce 
an autoimmune response against IgE and thereby reduce the levels of total IgE. The 
assumption was that also antigen-specific IgE would be reduced and that it would in that way 
decrease the allergic symptoms. The dogs were treated with high levels of anti-IgE antibodies, 
which resulted in a 65% decrease of the mean IgE-levels. This shows that vaccine treatment 
may be possible as a future therapy of allergic dogs (Ledin et al, 2006). 
 
Candidate genes for Canine Atopic Dermatitis 
Based on studies in human patients with skin disorders and in murine models of AD, the two 
genes Kallikrein 7 (KLK7) and Serine Protease Inhibitor Kazal-type 5 precursor (SPINK5) 
were chosen in the present study as candidate genes for CAD. KLK7 has shown to be 
involved in important mechanisms in the human skin and may play a part in psoriasis. 
SPINK5 has shown linkage to AD in humans as well as involvement in another severe skin 
disease called the Netherton Syndrome (NTS). Both genes are presented below. 
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The functional role of Kallikrein 7  
Desquamation 
 
The stratum corneum is the outermost layer of the epidermis. The corneocytes are cells 
without nucleus in the stratum corneum representing the last stage of the epidermal 
differentiation process. Corneocytes consist primarily of keratin filaments surrounded by a 
cross-linked protein envelope. The stratum corneum has a high mechanical resistance, which 
is dependent on the cohesion between individual corneocytes. This cohesion is mediated 
mainly by modified desmosomes. There is a constant production of corneocytes since a 
fraction of epidermal cells continuously leaves the proliferating basal layer and undergoes 
differentiation. In order to achieve a constant and well-regulated stratum corneum thickness 
there is a continuous process of cell shedding at the skin surface. This mechanism is called 
desquamation which means elimination of stratum corneum cell cohesion in surface cell 
layers. Proteolysis of intracellular cohesive structures has shown to be of major importance in 
the series of events that precede desquamation (NCBI´s homepage). 
 
Kallikrein 7 
 
KLK7, also called the stratum corneum chymotryptic enzyme (SCCE), is a serine protease 
that is specifically expressed in cornifying squamous epithelia (Ekholm & Egelrud, 1999). It 
is thought to be involved in the desquamation process through proteolysis of intracellular 
adhesion molecules such as desmoglein. In a study by Ishidia-Yamamoto et al, 2005, KLK7 
was localized in lamellar granules and more specifically detected in a thin zone at the border 
between the stratum granulosum and stratum corneum as well as in the stratum corneum. 
KLK7 may also have other functions unrelated to desquamation i.e. it has shown to be active 
in catalyzing the creation of active interleukin-1β (IL-1 β) from pro-IL1 β, thus indicating a 
role in inflammation (Johnson et al, 2003). According to Ekholm & Egelrud´s study in 1999 
the expression of SCCE in psoriatic skin lesions in humans was found to be consistently 
increased compared to normal skin. It was, however, not known if this was a secondary effect 
but it indicated that SCCE may play a part in the aetiology of psoriasis.  
 
The results from a study by Johnson et al, 2003, suggest that KLK7 is expressed abnormally 
in skin where epidermal cell kinetics is disrupted due to inherited or acquired defects. 
 
Serine Protease Inhibitor Kazal-type 5 precursor 
 
The gene SPINK5 is encoding the serine protease inhibitor; Lympho-epithelial Kazal-type 
related inhibitor (LEKTI). LEKTI consists of 15 potential Kazal-type serine proteinase 
inhibitory domains (D1-D15) and is expressed in the most differentiated viable layers of 
stratified epithelial tissue. LEKTI in the epidermis is mainly restricted to the granular layer 
(Descargues et al, 2005), which is the top layer of transcriptionally active keratinocytes, 
located under the stratum corneum (Galliano et al, 2005). It is in the granular layer the crucial 
biochemical and morphological changes occur during stratum corneum formation 
(cornification) (Descargues et al, 2005).  
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LEKTI is secreted from the keratinocytes and its possible targets are KLK7 and KLK5 
(Kallikrein 5, also called Stratum Corneum Tryptic enzyme (SCTE)). In a study by Ishidia-
Yamamoto et al, 2005, LEKTI and KLK7 were detected in the lamellar granules but localized 
separately, with LEKTI detected in the deeper epidermal layers and KLK7 in more superficial 
layers. The findings from the study suggest that LEKTI is expressed and released earlier than 
its target proteases (KLK7 and KLK5). Combined, these results show that LEKTI has a role 
in preventing premature proteolysis of extracellular matrix proteins or cell surface adhesion 
molecules thus controlling the timing of desquamation.   
 
Netherton Syndrome 
 
SPINK5 has recently been shown to be defective in NTS which is a severe autosomal 
recessive human skin disorder characterized by congenital ichthyosiform erythroderma, a 
specific hair shaft defect and atopic manifestations. (Descargues et al, 2005) Ichthyotic skin 
has an abnormal thick stratum corneum and the thickening is a result of hyper-proliferation of 
the epidermal keratinocytes and/or increased corneocyte adhesion. (Komatsu et al, 2002) 
Individuals affected with NTS have a wide range of allergic manifestations such as AD and 
elevated IgE levels which are associated with chronic and severe skin inflammation. In NTS, 
a common feature is the absence of LEKTI expression in the epidermis (Descargues et al, 
2005). 
 
In NTS patients, the mutations in the SPINK5 gene results in a truncated pro-protein 
containing fewer inhibitory domains compared with the normal protein. From this follows that 
KLK7 and KLK5, which are both targets of the inhibitors, are over-activated and this leads to 
increased degradation of desmoglein 1 (a cell-adhesion molecule crucial for corneocyte 
adhesion), thus resulting in an over-desquamation of corneocytes (Komatsu et al, 2002). 
 
Knock-out mice studies 
 
According to a study by Descargues et al, 2005, LEKTI deficiency results in abnormal 
desmosome cleavage in the upper granular layer, which leads to a defective stratum corneum 
adhesion and therefore loss of skin barrier function. The study was performed on knock-out 
mice, SPINK5-/-, with the aim to investigate the biological functions of LEKTI. The main 
conclusion from the study was that LEKTI plays a crucial role in epidermal desquamation, 
keratinisation, barrier formation and hair morphogenesis. The most notable defect observed in 
the SPINK5-/- mice was the loss of adherence of stratum corneum, which underlies the severe 
epidermal fragility. 
 
Linkage to Atopic Dermatitis in humans 
 
In a report by Walley et al, 2001, six coding polymorphisms in the human SPINK5 gene were 
identified. One of these (Glu420-Lys) showed significant association with atopy and AD in 
two independent sets of families. 
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Tools in molecular genetic studies 
Genetic polymorphisms 
 
Genomes consist of polymorphisms, which are sequences that are found in two or more 
variants within a population. Single-nucleotide polymorphisms (SNPs) and insertion/deletion 
polymorphisms (indels) represent the majority of the variation in the genome. SNPs and 
indels are used to identify loci responsible for a genetic component of a multifactorial 
phenotypic variation such as disease susceptibility. First, the distribution of SNPs (or indels) 
must be characterized before an association between a genotypic polymorphism and a certain 
phenotype can be found. An additional important aspect to consider is the level of haplotype 
structure due to non-random associations between sites i.e. linkage disequilibrium (LD). A 
haplotype is a set of adjacent polymorphisms linked together on the same chromosome 
(Gibson & Muse, 2004). 
 
Only 30-50% of all SNPs have the rare allele present in more than 5% of the individuals 
within a population. This means that a SNP found in one population might not be useful in 
mapping experiments of another population. Another relevant aspect of frequency distribution 
is nucleotide diversity i.e. the average fraction of nucleotides that differ between a pair of 
alleles chosen at random from a population. Humans have a nucleotide diversity of one SNP 
every kilobase (kb), which is fairly low. Another aspect is that the amount of variation within 
a locus differs between different parts of the genome e.g. between introns and exons (Gibson 
& Muse, 2004). 
 
LD can arise from a variety of sources such as non-random mating, population admixture and 
epistatic selection (Gibson & Muse, 2004). Dogs have a higher degree of LD within a 
particular breed compared to humans resulting in longer haplotypes in the dog genome (Sutter 
et al, 2004). This is an effect from the dog’s population structure, which has a history of 
intense inbreeding and a restricted amount of founders within a breed. Due to the long 
haplotypes, less SNPs are needed in order to evaluate a greater distance of the genome. 
 
Microsatellites 
 
Microsatellites are short simple sequence tandem repeats with a repeat length up to 13 bases 
(longer repeats are called minisatellites). The most common microsatellites are built up by 
permutations of di-nucleotide repeats. They are highly abundant in the mammalian genomes 
and are perhaps the most variable form of DNA sequences known to exist within these 
genomes. Their polymorphism is caused by length variation of the particular repeat-unit e.g. 
(CA)n. The frequency distribution of di-nuclotide repeats is: (CA)n>(AT)n>(GA)n>(GC)n.  
Microsatellite-DNA represents around three percent of the human genome and is distributed 
at more than one million loci with the following frequency distribution: (di)n, (mono)n, (tetra)n 
and least frequent are (tri)n-repeats. (International Human Genome Sequencing Consortium, 
2001) Microsatellites occur at an approximate rate of one repeat per 10 kb in eukaryotic 
genomes, and can be very useful as genetic markers since they are extremely polymorphic 
with the presence of multiple alleles within a population (Gibson & Muse, 2004). 
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This study 
 
The primary objective of this project was to search for possible associations between genetic 
markers, in the vicinity of the chosen dog genes, and the disease phenotype. Bioinformatics 
was used to find suitable genetic markers near the two candidate genes described above. 
Three microsatellites in the near vicinity of KLK7 were localized and one intron of SPINK5 
was chosen to be sequenced in order to identify informative SNPs. 
 
Materials and Methods 
Bioinformatics 
 
The candidate genes chosen for this study were at the time not annotated in the available dog 
genome sequences but were found in ENSEMBL by aligning the human SPINK5 and KLK7 
gene to the dog’s genome (ENSEMBL´s homepage).  
 
In dog, SPINK5 is located on chromosome 2 (Cfa2) at location 42,886,822-42,957,059. It 
consists of 29 exons and has a transcript length of 3,075 base pairs (bp). 
 
In dog, KLK7 is located on chromosome 1 (Cfa1) at location 108,156,349-108,159,472. It 
consists of 5 exons and its transcript is 774 bp long.  
 
Sample collection 
 
Blood samples from dogs diagnosed with the Willemse´s criteria for CAD, after elimination 
of different diagnoses such as pyoderma, parasites and CAFR, were collected from 12 
veterinary clinics throughout Sweden. The samples were collected between the years 2002 
and 2005 and are part of a larger study on naturally occurring canine models of multifactorial 
diseases where both epidemiological and molecular genetic studies are performed. The 
multidisciplinary project is performed in collaboration between the Department of Small 
Animal Clinical Sciences and the Department of Animal Breeding and Genetics, at SLU. The 
identification of risk factors for CAD will be aided by utilizing unique features of Swedish 
breed populations. Control animals were chosen at random from the database of the Swedish 
Kennel Club (SKK) (Nødtvedt et al, in press). 
 
Most of the dogs used in this study are listed in the SKK´s register and the dogs’ pedigrees 
were collected from SKK´s database. The parents of the dogs used in this study were defined 
and compared, leading to the discovery that some test individuals were related to each other. 
 
DNA extraction 
 
Genomic DNA was isolated using a salt extraction method, see Appendix 1. Some of the 
samples were already extracted by standard methods such as the Phenol-Chlorophorm method 
and with the E.Z.N.A® Kit; Blood & Body Fluid DNA Spin Protocol. The DNA sample 
concentrations were measured by the Nanodrop ND-1000 Spectrophotometer and were then 
diluted with dH20 to 25 ng/µl.  
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PCR amplification 
 
Primers were designed using Primer 3 software (Primer3 Software’s homepage) and ordered 
from TAG Copenhagen A/S online (Tag Copenhagen’s homepage). The Polymerase Chain 
Reactions, PCRs, were run with the 2720 Thermal Cycler (Applied Biosystems). 
 
Kallikrein 7 
 
For each of the three microsatellites one primer pair was designed. The first microsatellite, 
called Klk71, had the primer sequences; Klk71F: 5´-TCCCACATTAGGCTCTCTGC-3´ and 
Klk71R: 5´-CACGAATCCAAACCCAATTC-3´. Klk71 consists of a CT-repeat and is 
located 2.3 kb in front of the gene. The total product size, according to ENSEMBL, was 169 
and it consisted of 15 repeats. The second microsatellite, Klk72, had the following primers; 
Klk72F: 5´-ATGGGGATGGTTCATGATGT-3´ and Klk72R: 5´-
TGAGATCCACAGGAGATGGA-3´. Klk72 consists of a TG-repeat and is located 7 kb in 
front of the gene. It had 16 repeats and a product size of 249 bp according to the sequence in 
ENSEMBL. The third microsatellite, Klk73, is located 2.3 kb behind the gene and consists of 
a tetra repeat (TTTA)n. The following primers were designed for the third microsatellite; 
Klk73F: 5´-CCGGTACTTTTGCCCACTTA-3´ and Klk73R: 5´-
TTAGGGTCAAGCCCTGTGTC-3´. The product size of Klk73 was 203 bp and it had 10 
repeats. 
 
Instead of labelling each primer pair with dyes for the genotyping laser detection system, a 
universal fluorescent-labelled M13 (-21) primer was used. All forward primers in each pair 
were ordered with a M13 (-21) tail at its 5´-end, which had the following sequence; 5´-
CACGACGTTGTAAAACGAC-3´. During the first PCR cycles, the forward primers with the 
M13 (-21) tail are incorporated into the PCR products. The incorporated tails are then targets 
for the labelled universal M13 (-21) primer. This primer is then included during the remaining 
cycles which results in a labelled and slightly longer product. The fluorescent dyes used in the 
PCR were FAM (6-carboxy-fluorescine) for Klk71 and Klk72, and TET (tetrachloro-6-
carboxy-fluorescine) for Klk73 (Schuelke, 2000).  
 
After experiencing some problems with optimizing the PCR program, the following mix and 
program was used successfully for all the microsatellites. 25 ng genomic DNA was amplified 
with 0.02 µM of the forward primer, 0.2 µM of the reverse primer as well as of the labelled 
universal M13(-21) primer, 0.5 U of AmpliTaq Gold (Applied Biosystems), 0.2 mM 
deoxyribonucleoside triphosphate (dNTP), 1x PCR Buffer and 2.0 mM MgCl2 in a final 
volume of 12.5 µl. The PCR program consisted of a denaturation step of 5 min at 94ºC, 
followed by 40 cycles of 30 s 94 ºC, 30 s 52 ºC, 25 s 72 ºC and finally an extension step for 
15 min in 72 ºC.  
 
Serine Protease Inhibitor Kazal-type 5 precursor  
 
The primers were located in intron five and six and were designed to cover almost all of 
intron five as well as exon six resulting in a total product size of 1497 bp. The PCR-primer 
sequences were; Spink5F: 5´-TAGAAATAGTCCTTGCTTTCTG -3´ and Spink5R: 5´- 
TCCTTCAAAGATTCAAGCCTA – 3´. Also, one forward and one reverse primer were 
designed for sequencing. These were located in the first part of the fragment with a small 
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overlap. The sequencing primers were, Spink5seqF: 5´-AATGTGGAGAAGATCCAATG- 3´ 
and Spink5seqR: 5´-AAGCCTGCTGACATACAGAT- 3´.   
 
For each PCR, after optimization; 50 ng of genomic DNA was amplified with 0.2 µM of each 
of the PCR-primers, 1.0 U of AmpliTaq Gold (Applied Biosystems), 0.2 mM dNTP, 1x PCR 
Buffer and 1.5 mM MgCl2 in a final volume of 25 µl. The PCR program consisted of a 
denaturation step of 5 min at 94ºC followed by 40 cycles of 40 s 94 ºC, 40 s 55 ºC, 3 min 72 
ºC and at last an extension step for 5 min in 72 ºC.  
 
Gel extraction and sequencing preparation 
 
To confirm the identity of the fragments, the PCR products were separated on 2% agarose gel 
(SeaKem®GTG®Agarose and 0.5xTBE). 
 
The SPINK5 fragments were excised from the gel and DNA was extracted with the E.Z.N.A® 
Kit Gel Extraction Protocol. The fragments were then prepared for sequencing with the kit; 
DYEnamic ET Dye Terminator Cycle Sequencing Kit for MegaBACE DNA Analysis 
Systems (Amersham Biosciences). In step 1.2 of the Kit manual the 384-well format was 
chosen. The mix consisted of a total of 250 ng DNA (for a product size of 1500 kb), 1 µl of 
primer with a concentration of 5 pmol/µl, 4 µl sequencing reagent premix and water until a 
total volume of 10 µl was reached. For step 1.4 the program was changed from 1 to 1.5 min 
for the 60ºC step. In part 2.1.2 30 µl of 95% ethanol was added to each reaction. Before the 
samples were run on the MegaBACE 10 µl MegaBACE loading solution was added 
according to step 3.1. 
 
MegaBACE 1000 
 
The MegaBACE 1000 was used for sequencing of the SPINK5 fragments and for genotyping 
of the KLK7 microsatellites. The buffer plates (one new for each run) consisted of 1x 
MegaBACETM LPA Buffer (Amersham Biosciences). The buffer as well as the sample plates 
were centrifuged 2 min 1000g and the MegaBACE Long Read Matrix (Amersham 
Biosciences) were centrifuged 3 min 3000g before each run. 
 
For the genotyping of KLK7 microsatellites, each well of the MegaBACE plate consisted of 1 
µl of the PCR product and 5 µl of MegaBACETM ET400-R size standard (diluted 1:20). 
 
For the sequencing of the SPINK5 fragment, the set up of the instrument parameters were 
according to step 4.3 (MegaBACE 500 and 1000) in the manual used for sequencing 
preparations.  
 
Analysis 
 
The primary data from the MegaBACE run of the microsatellites were analyzed with the 
MegaBACETM Genetic Profiler version 2.2 (Amersham Biosciences). For analyzing of the 
sequences of the SPINK5 gene the Software; SequencherTM 3.1.1, was used. 
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The contingency calculations for the analysis of genetic linkage were preformed with the 
program CONTING version 2.71 (Utility programs for analysis of genetic linkage, copyright 
1988, J. Ott). 
 
Results 
Kallikrein 7 
Relationships 
 
Half siblings, full siblings and two cousins were found after the comparison of the dogs’ 
parents.  
 
In the Boxer group, dog 41 and 42, and, dog 28 and 1 were pairs of half siblings (the first dog 
in each pair was a control dog and the second was a case). Two full sibling pairs were found 
as well; dog 17 and 49 (both cases) and 16 and 19 (both controls). See Appendix 2, controls 
are marked green and cases red. 
 
In the WHWT group, dog 3 and 44 (both cases), dog 21 (control) and 25 (case), and, dog 34 
and 57 (both controls) were pairs of half siblings. The dogs 45, 47 and 50 (the two first were 
cases and the last was a control), and, dog 29, 31 and 41 (all controls) were triplets of half 
siblings. One full sibling pair was found; the control dogs 43 and 15. Dog 28, control, was 
cousin to the half sibling group of 29, 31 and 41. See Appendix 3. 
 
Allele distribution of microsatellites 
 
For Boxer, three different alleles were found within each of the three microsatellites, except 
for Klk71 where a fourth allele was found in dog 34. The alleles could be connected into four 
probable haplotypes (the fourth allele of Klk71 not included). See appendix 2 for the results 
from the genotyping. In the case where not all three microsatellites worked, the haplotype is 
marked with a question mark and is included in the calculations within the square brackets.  
The distribution of alleles and the haplotypes did not show any significant association to case- 
or control animals, on the other hand they were significantly equally distributed. This trend 
was also seen when the alleles of the microsatellites were calculated separately. See the 
analysis of genetic association with contingency calculations of the alleles and haplotypes in 
Appendix 4. 
 
For WHWT, four different alleles were found within Klk72 and Klk73, and two clear and one 
uncertain allele were found within Klk71. See Appendix 3 for the results. The alleles found in 
WHWT could not be connected into any probable haplotypes but calculations could be made 
concerning the allele frequency in cases and controls. The alleles were equally distributed 
over cases and controls, thus no significant associations could be seen between a certain allele 
and the disease phenotype. For the calculations, see Appendix 4. 
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Serine Protease Inhibitor Kazal-type 5 precursor 
Relationships 
 
In the Boxer group there was one pair of half siblings, which consisted of one case (dog 42) 
and one control animal (dog 41). No relationships were found between any of the WHWTs 
used in the SNP-analysis of SPINK5. 
 
SNPs and haplotypes 
 
The SNPs found within the sequenced fragment of SPINK5 are shown in Figure 1 below. 
 
 
            Intron 5: gtaagtattatcatccccaagcagaccaagtaggtggacttgatgaggatgcacttggtg 
atatcctgagaactgctccacagagagatacagtccttttcatgaaacatacaattcttt 
gtcttcacaagttgaaatagtccttgctttctgagtggcttctttttagttctttcattt 
gctagaatttcttaaaaggcatagataaggtgattatgttaattattaaattcaaaacgc 
ttaatatgcttaattacaatgataggacaatgcatggtgttttataaggtacagtatttt 
aaaatttagaaaacactttcctagaataatctagtttggtcttttgatgt[a/g]cattgcttc 
atttgaatgtgtatagagattcttactaaaagagacagtctaatttaaattaataataat 
aacaata[g/a]tgtcatgtggctgcctttcattatgaatataaaaggtgaaaaaaatgaatata 
aaaggtggaactttaggaaagggaagaatagggttaactttctctgagtgcctgtcatct 
tgagtactgaggctgcaatgtggagaagatccaatgagtctttaatattctggcagttaa 
acaaggtatagactctctaatctgtatgtcagcaggctttaaagtgctccagttatatc[c/t] 
atggatttttaaaatcaagacagagaaagatttaaccagatcaataaatttca[c/a]acctgcc 
tttgaaaattacagtgtgctggttagagaattcaagggcag[a/g]tcctatcaggtttacaaa 
acagtgattatatctggtttccagacaggaaataagcctaatttctactttcttatctag 
aagacatgtgcctatagtgttccaacctgccccagttctgtgactttctgtttgttttca 
tgcactagctaaaaaagagaatttgacctcttggtttaactcttggtttcatcctctgta 
gaactaataatgcctgtctctgggatgagaatgtaattaggtaacagatatgagaggact 
tagaagctcagttcaatgtggctttttttttattattttaacggcggtgattttacatga 
aggcaaacaaatactttataaggtatagaaaaggtttgcataagggtgtggacggcaata 
cctcaaatgctcagtttggtttcacccttgtcacagcgttgtgttaaaaagctcttggtt 
ctgccagttaaagggaattttccggacaatcttctgtttgtcaatcaaggagtcacaccc 
atctactcttaaagtacaaagcttctaattg[t/:]actgtca[g/:]gtgagtcagtttcacacccttc 
cttatctttggcaattttctggctagaattcaagacagggaaaaggc[gtg/:]tgtgtcatgtaaa 
tcgattggtttcacaagttatggccaaggataggaaagtgcctagcacagaat[g/:]tggacac 
caaaaatatgattgagccataaactgaccag[t/:]ctgttctctttcttaacag 
           Exon 6: CTTAAAAGAAGCTCAAGAAAATGCCAAGAGAGCAAGTGAAGCCAGAATTCGAAGAAGTGC 
CAAAAAC 
        Intron 6:         CGTAAATTACTCACCGACATATTTTGGTCTTGTGGCCAAAGTGTTAACAAAATTAGGCTT 
            GAATCTTTGAGGAATTCAATAATG 
 
Figure 1. The sequenced fragment of SPINK5 and found SNPs. 
 
Sequences marked yellow in the figure are the PCR-primers and sequences marked blue and 
grey are forward and reverse sequence primers, respectively.  
 
Dog 4 (WHWT) had two insertions; [t/:], marked green, and [g/:], marked blue, and was 
heterozygote for [c/t] (other dogs were homozygotes for c) at the blue marked position, in the 
picture above. Dog 20 (WHWT) had three insertions; [gtg/:], marked purple, [g/:] and [t/:], 
both marked red. 
 
The following SNPs; [a/g] [g/a] [c/a] and [a/g] were found in Boxer (marked grey and bold in 
the picture). These could be matched together into two haplotypes; AGCA and GAAG. The 
GAAG haplotype was fixed in WHWT but in Boxer the two haplotypes were found in an 
about 70:30 ratio. Calculations were made on the distribution of the haplotypes between cases 
and controls in Boxer, and no associations could be seen between any of the two haplotypes 
and the disease phenotype. See Appendix 5 for the haplotype distribution and contingency 
calculations. 
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Discussion 
Kallikrein 7 
 
The results from the analysis of Klk71 were difficult to interpret and some samples were re-
run in order to get more reliable results. In WHWT some peaks looked as if they were one 
base shorter than the common allele 196 (in WHWT), but in the second and third run the 
majority of the peaks were estimated to be 196 long. However, two individuals still had peaks 
which were not easily interpreted even after the re-runs. One of these (47) had a half sibling 
which was homozygote for the 196 allele, therefore this animal would possibly also carry the 
196 allele. The 194 allele found in dog 4 was the one exception from the probably fixed 196 
allele in the WHWT. This genotype was fairly definite in its interpretation, since this dog was 
heterozygote for the 196 and the 194 allele, and no errors could be the cause of this 
estimation. This dog also had rare alleles in the other loci, which indicates that it is less 
related to the other dogs. Since the rare alleles are found only in this dog, they were not 
possible to include in the contingency calculations of allele distribution.  
 
In Boxer, the peaks from the genotyping of dog 41 was difficult to interpret, but was with the 
help of the probable haplotypes estimated to have the alleles 188/190 in Klk71. 
 
The results from calculations of the allele (WHWT and Boxer) and haplotype (Boxer) 
distributions indicated with statistical significance that there are no associations between 
KLK7 and the disease phenotype.  
 
Serine Protease Inhibitor Kazal-type 5 precursor 
 
No haplotypes or SNPs, except individual mutations, were found in WHWT, thus conclusions 
about the gene’s involvement in the disease within this breed can not be drawn. The data 
shows that the breed probably has a high degree of inbreeding, which explains the lack of 
polymorphisms in the genome.  
 
In Boxer, the two haplotypes within the SPINK5 gene shows an equal distribution between 
healthy and sick dogs. However, the haplotype found in this study covers only a small 
fragment of the genome. This, as well as the fact that there are very few animals included in 
the study contributes to a low trustworthiness of the results. The results demonstrate breed 
differences between WHWT and Boxer, showing that the four found SNPs are fixed in 
WHWT but are polymorphic in Boxer. 
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Conclusions 
The data obtained in this study indicates that the gene KLK7 is not associated with the disease 
development in Boxer or WHWT. However, if more animals were tested the results would 
become even more reliable. 
 
Further studies are necessary in order to draw any conclusions concerning the potential 
involvement of SPINK5 in CAD. SPINK5 should be searched for informative microsatellites 
in the near vicinity of the gene, so that a similar approach as for the KLK7 gene can be 
performed. This should lead to more polymorphic markers covering a greater distance. In 
addition, more animals (cases and controls) must be tested in order to evaluate the SPINK5 
gene.   
 
Future research 
The Department of Small Animal Clinical Sciences and the Department of Animal Breeding 
and Genetics, at SLU, are under the process of collecting more samples from CAD-affected as 
well as healthy dogs of a total of 12 different breeds. These samples, optimally 100 cases and 
100 controls within each breed, will be used in a genome-wide association mapping with a 
panel of 20,000 SNPs. This will hopefully lead to the characterization of a specific region 
within the genome that is associated with the disease. Candidate genes within this region can 
then be evaluated further by fine-mapping.  
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Appendix 1. DNA extraction protocol 
 
1. Mix 200 µl blood and 200 µl Buffer A in sterile eppendorph tubes. Turn tubes to 
lysate the cells. 
2. Centrifuge for 10 min in 4 ºC in 3000 RPM. 
3. Discard the liquid phase carefully and mix the pellet with 300 µl of Buffer A. 
4. Redo step 3 until the pellet is light, at least three times. 
5. Mix pellet thoroughly with 90 µl of Buffer B. 
6. Add 10 µl of Buffer C. The solution should now be viscous. 
7. Incubate over night in 50 ºC. 
8. Add 27 µl saturated NaCl solution (around 6 M, salt crystals should be seen in the 
bottom) and shake roughly for 15 seconds.  
9. Centrifuge for 15 minutes in 3000 RPM. Move the liquid phase to new tubes.  
10. Redo step 9 once. 
11. Add 250 µl of cold EtOH. Turn tube. 
12. Pick up the DNA with a pipette tip. Transfer the DNA into a new tube with 1xTE or 
dH2O (around 30 µl). 
 
 
Buffer A 
0.32 M Sucrose (109.5g) 
1 mM TrisHCl ph 7.5 (1 ml, 1 M) 
5 mM MgCl2 (5 ml, 1M) 
1 % Triton-X (10g) 
Add dH2O until the solution has a volume 1000ml. 
Autoclave in 105 ºC   
Store in refrigerator 
 
Buffer B 
400 mM NaCl (100 ml, 4M) 
2 mM EDTA pH 8.0 (10 ml, 0.2M) 
10 mM TrisHCl pH 8.0 (10ml, 1M) 
Add dH2O until the solution has a volume 1000ml. 
Autoclave in 105 ºC 
Store in refrigerator  
 
Buffer C (make fresh the same day) 
5 % SDS (200 µl of 10 % solution) 
2 µg/µl Proteinase K (100 µl from a stock solution of 8 µg/µl into dH2O) 
100 µl dH2O 
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Appendix 2. Results from genotyping of the KLK7 microsatellites in Boxer 
Klk71 Klk72 Klk73
Indiv. Diagnosis Allele1 Allele2 Allele1 Allele2 Allele1 Allele2 Haplotype1 Haplotype2
2.6.1 Case 188 188 272 272 224 224 A A
2.6.6 Case 190 190 280 280 212 212 B B
2.6.7 Case 188 188 272 272 224 224 A A
2.6.9 Case 188 196 272 276 224 228 A C
2.6.10 Case 190 190 280 280 212 212 B B
2.6.11 Case 196 196 276 276 228 228 C C
2.6.12 Case 188 196 272 276 224 228 A C
2.6.14 Case 188 188 272 280 224 224 A D
2.6.17 Case 188 196 272 276 224 228 A C
2.6.18 Case 188 196 272 276 224 228 A C
2.6.22 Case 188 196
2.6.29 Case 188 188 272 272 A? A?
2.6.31 Case 188 188 272 272 224 224 A A
2.6.35 Case 188 196 272 276 224 228 A C
2.6.36 Case 190 190 280 280 212 212 B B
2.6.37 Case 188 188 272 272 A? A?
2.6.38 Case 196 196
2.6.39 Case 280 280
2.6.42 Case 190 196 276 280 212 228 B C
2.6.46 Case 188 190 272 280 A? B?
2.6.49 Case 188 196
2.6.50 Case 188 188
2.6.51 Case 188 188
2.6.52 Case 188 188 272 272 A? A?
2.6.53 Case 188 196 25
2.6.15 Control 188 196 272 276 224 228 A C
2.6.16 Control 188 196 272 276 224 228 A C
2.6.19 Control 188 188 272 280 224 224 A D
2.6.24 Control 272 272 224 224 A A
2.6.25 Control 188 188 272 272 224 224 A A
2.6.26 Control 188 188 272 272 224 224 A A
2.6.27 Control 188 196 272 276 224 228 A C
2.6.28 Control 188 188 272 272 224 224 A A
2.6.32 Control 188 196 272 276 224 228 A C
2.6.33 Control 190 196 276 280 B? C?
2.6.34 Control 188 198 272 276 A? ?
2.6.40 Control 188 188 272 272 224 224 A A
2.6.41 Control 188? 190? ? 272 280 212 224 A B
2.6.43 Control 188 196 272 276 224 228 A C
2.6.44 Control 190 196 276 280 212 228 B C
2.6.45 Control 188? 196? 272 276 A? C?
2.6.47 Control 190 196 276 280 212 228 B C
2.6.54 Control 188 188 272 272 224 224 A A 18
Haplotypes: A: 188 272 224 Half siblings Full siblings
B: 190 280 212 2.6.41 2.6.42 2.6.17 2.6.49
C: 196 276 228 2.6.1 2.6.28 2.6.16 2.6.19
D: 188 280 224
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Appendix 3. Results from genotyping of the KLK7 microsatellites in WHWT 
Klk71 Klk72 Klk73
Indiv. Diagnosis Allele1 Allele2 Allele1 Allele2 Allele1 Allele2
3.33.1 Case 196 196 278 280 228 232
3.33.2 Case 196 196 280 280 228 232
3.33.3 Case 196 196 278 278 228 228
3.33.4 Case 194 196 274 274 224 228
3.33.6 Case 196 196 278 278 228 228
3.33.16 Case 196 196 278 280
3.33.25 Case 196 196 278 280 232 236
3.33.26 Case 196 196 278 280 228 232
3.33.27 Case 196 196 280 280
3.33.30 Case 196 196 278 280 228 228
3.33.37 Case 195? 195? 280 280 228 228
3.33.38 Case 278 278 228 228
3.33.42 Case 196 196 280 280
3.33.44 Case 196 196 278 280 228 232
3.33.45 Case 278 278
3.33.46 Case 280 280 228 232
3.33.47 Case 196 196 278 280 228 228
3.33.48 Case 196 196 278 280
3.33.51 Case 278 280 228 228
3.33.54 Case 278 280 20
3.33.8 Control 196 196 278 280 228 228
3.33.13 Control 196 196 280 280 232 232
3.33.14 Control 196 196 278 280 228 232
3.33.15 Control 278 280
3.33.18 Control 196 196 278 280 228 232
3.33.19 Control 196 196 278 278 228 228
3.33.20 Control 196 196 278 280 228 232
3.33.21 Control 196 196 278 280 228 236
3.33.22 Control 196 196 278 280 228 228
3.33.23 Control 196 196 278 280 228 228
3.33.24 Control 196 196 278 280 228 228
3.33.28 Control 196 196 280 280 232 232
3.33.29 Control 196 196 280 280
3.33.31 Control 276 280 228 232
3.33.32 Control 196 196 278 278 224 228
3.33.33 Control 280 280 228 228
3.33.34 Control 278 278 228 228
3.33.39 Control 196 196 280 280 228 232
3.33.41 Control 280 280 228 232
3.33.43 Control 196 196 278 280 228 232
3.33.49 Control 196 196 280 280 228 232
3.33.50 Control 196 196 278 280 228 232
3.33.53 Control 278 280 228 228
3.33.55 Control 280 280 228 228
3.33.56 Control 278 280
3.33.57 Control 278 278 228 228 26
Half siblings Full siblings
3.33.3 3.33.44 3.33.43 3.33.15
3.33.21 3.33.25
3.33.47 3.33.50 3.33.45 Cousins
3.33.34 3.33.57 3.33.28 is cousin to the halfsibling group of 3.33.29, 31 and 41.
3.33.29 3.33.31 3.33.41  
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Appendix 4. Analysis of genetic associations with contingency calculations 
 
WHWT Klk71
Alleles 194 195 196 No. Alleles
Cases (O) 1 2 27 30
Controls (E) 0 0 34 34
Chi square test (2 d.f.): 3.57
2-sided p-value: 0.16
WHWT Klk72
Alleles 274 276 278 280 No. Alleles
Cases (O) 2 0 18 20 40
Controls (E) 0 1 21 30 52
Chi square test (3 d.f.): 3.73
2-sided p-value: 0.29
WHWT Klk73
Alleles 224 228 232 236 No. Alleles
Cases (O) 1 20 6 1 28
Controls (E) 1 31 13 1 46
Chi square test (3 d.f.): 0.61
2-sided p-value: 0.89
Boxer Klk71
Alleles 188 190 196 198 No. Alleles
Cases (O) 27 8 13 0 48
Controls (E) 20 4 9 1 34
Chi square test (3 d.f.): 1.76
2-sided p-value: 0.62
Boxer Klk72
Alleles 272 276 280 No. Alleles
Cases (O) 19 8 11 38
Controls (E) 21 10 5 36
Chi square test (2 d.f.): 2.52
2-sided p-value: 0.28
Boxer Klk73
Alleles 212 224 228 No. Alleles
Cases (O) 7 13 8 28
Controls (E) 3 20 7 30
Chi square test (2 d.f.): 3.09
2-sided p-value: 0.21
Haplotypes Boxer A B C D No. Hapl.
 (in parntesis; all haplotypes incl. individuals with results from only two microsatellites)
Cases, O 12 (19) 7 (8) 8 1 28 (36)
Controls, E 19 (21) 3 (4) 7 (9) 1 30 (35)
Chi square test (3 d.f.): 3.18 (1.48)
2-sided p-value: 0.36 (0.69)
Chi square distribution (0.05 level of sign.)
3 d.f. 7.81
2 d.f. 5.99  
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Appendix 5. SNPs found in the intron of the SPINK5 gene 
 
Individual Diagnosis Locus 1 Locus 2 Locus 3 Locus 4 Haplotype 1 Haplotype 2 
Boxer
2.6.17 Case A/A G/G C/C A/A AGCA AGCA
2.6.31 Case A/G G/A C/A A/G AGCA GAAG
2.6.35 Case G/G A/A A/A G/G GAAG GAAG
2.6.36 Case A/A G/G C/C A/A AGCA AGCA
2.6.38 Case A/G G/A C/A A/G AGCA GAAG
2.6.42* Case A/G G/A C/A A/G AGCA GAAG
2.6.32 Control A/A G/G C/C A/A AGCA AGCA
2.6.40 Control A/A G/G C/C A/A AGCA AGCA
2.6.41* Control A/A G/G C/C A/A AGCA AGCA
2.6.44 Control A/A G/G C/C A/A AGCA AGCA
2.6.47 Control A/G G/A C/A A/G AGCA GAAG
2.6.54 Control G/G A/A A/A G/G GAAG GAAG
WHWT
3.33.4 Case G/G A/A A/A G/G GAAG GAAG
3.33.16 Case G/G A/A A/A G/G GAAG GAAG
3.33.26 Case G/G A/A A/A G/G GAAG GAAG
3.33.30 Case G/G A/A A/A G/G GAAG GAAG
3.33.6 Case A/A G/G     AG      AG
3.33.8 Control G/G A/A A/A G/G GAAG GAAG
3.33.19 Control G/G A/A A/A G/G GAAG GAAG
3.33.20 Control G/G A/A A/A G/G GAAG GAAG
3.33.23 Control G/G A/A A/A G/G GAAG GAAG
Boxer
Haplotypes AGCA GAAG No. Hapl. No. Indiv.
Cases, O 7 5 12 6
Controls, E 9 3 12 6
Chi square test (1 d.f.): 0.19
2-sided p-value: 0.665
Chi2 distribution (0.05 level of sign.)
1 d.f. 3.84
* Half siblings
 
 
